Louisville, Colorado, USA | March 20, 2026
Biodesix Inc. has announced the publication of the largest lung nodule biomarker clinical validation study ever conducted, reinforcing the clinical utility of its Nodify CDT® blood-based test for early lung cancer detection. The study, published in Future Oncology, evaluated over 1,100 patients across multiple cohorts, demonstrating high diagnostic accuracy and consistent performance across diverse patient populations and clinical settings, addressing a critical gap in lung cancer risk assessment.
Large-Scale Clinical Validation Confirms Diagnostic Accuracy
The retrospective pooled analysis included patients with noncalcified pulmonary nodules ranging from 4–30 mm, representing a common yet diagnostically challenging clinical scenario. The results showed that the Nodify CDT® test achieved high specificity of 91–97%, indicating low false-positive rates and strong reliability in identifying high-risk lung cancer cases.
Importantly, the study demonstrated consistent performance regardless of nodule size, baseline patient risk, or clinical setting, validating the robustness of the biomarker across four independent cohort studies and 48 clinical practices in the United States. This level of consistency is critical for clinical adoption and integration into routine diagnostic workflows, particularly in real-world healthcare environments.
Improving Early Diagnosis and Clinical Decision-Making
Advertisement
The findings highlight a major clinical challenge: millions of lung nodules are detected annually, yet distinguishing between benign and malignant nodules remains difficult using imaging alone. Current approaches often require clinicians to choose between “watchful waiting” or invasive diagnostic procedures, both of which carry risks.
By providing objective, blood-based biomarker insights, the Nodify CDT® test supports earlier and more accurate risk stratification, enabling clinicians to make timely intervention decisions. This is particularly important given evidence that over 40% of malignant nodules can progress in size before definitive diagnosis, potentially delaying treatment and impacting patient outcomes.
Clinical experts emphasize that integrating biomarker testing with imaging data can significantly enhance diagnostic confidence, reduce unnecessary procedures, and improve patient management pathways, ultimately leading to earlier cancer detection and better survival outcomes.
Implications for Clinical Practice and Healthcare Systems
The publication of this large-scale validation study strengthens the position of Nodify Lung® testing as a clinically actionable decision-support tool in lung cancer diagnostics. The ability to deliver consistent, high-specificity results across real-world practice settings underscores its potential to standardize lung nodule risk assessment and address variability in clinical decision-making.
From a broader healthcare perspective, the adoption of such biomarker-driven diagnostics can help optimize resource utilization, reduce unnecessary imaging or invasive procedures, and support evidence-based clinical pathways. The study also highlights the growing role of precision diagnostics and biomarker validation in oncology, aligning with the shift toward personalized medicine and early intervention strategies.
Additionally, the consistency between real-world dosing patterns and recommended clinical protocols confirms that the therapy can be effectively implemented in standard healthcare settings without significant deviations, a key consideration for Good Clinical Practice (GCP) and post-marketing surveillance frameworks.
Furthermore, the data provides a strong foundation for clinical guideline inclusion, payer acceptance, and expanded commercial adoption, reinforcing the value of robust clinical validation in driving diagnostic innovation.
The Biodesix study marks a significant advancement in lung cancer diagnostics, demonstrating that blood-based biomarker testing can deliver reliable, scalable, and clinically meaningful insights in real-world settings. With high specificity, consistent performance, and strong clinical applicability, the Nodify CDT® test represents a critical step forward in improving early lung cancer detection and patient outcomes, supporting the ongoing evolution of precision oncology diagnostics.
Source: Biodesix press release
